207 related articles for article (PubMed ID: 31765478)
41. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
Allahverdi N; Yassin M; Ibrahim M
Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
[TBL] [Abstract][Full Text] [Related]
42. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
43. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
44. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
45. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
46. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
47. Epidemiology of myeloproliferative neoplasms in the United States.
Mehta J; Wang H; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
[TBL] [Abstract][Full Text] [Related]
48. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
Mavrogianni D; Viniou N; Michali E; Terpos E; Meletis J; Vaiopoulos G; Madzourani M; Pangalis G; Yataganas X; Loukopoulos D
Int J Hematol; 2002 May; 75(4):394-400. PubMed ID: 12041671
[TBL] [Abstract][Full Text] [Related]
49. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
50. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
51. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
52. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
53. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
54. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.
Byun JM; Kim YJ; Youk T; Yang JJ; Yoo J; Park TS
Ann Hematol; 2017 Mar; 96(3):373-381. PubMed ID: 28028559
[TBL] [Abstract][Full Text] [Related]
55. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
56. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
[TBL] [Abstract][Full Text] [Related]
57. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
58. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
59. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
60. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
